We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARNA
126
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.36M 0.08%
+21,570
New +$1.43M
CGEN icon
127
CALL
Compugen
CGEN
$214M
$1.35M 0.08%
+1,287
New +$14.2K
FURX
128
CALL
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$1.32M 0.07%
+152
New +$11.7K
STAB
129
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$1.24M 0.07%
+91,308
New +$1.49M
CBST
130
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$1.21M 0.07%
+16,590
New +$1.24M
NVAX icon
131
Novavax
NVAX
$1.21B
$1.14M 0.06%
12,575
+11,075
+738% +$1.24M
GEVA
132
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.12M 0.06%
+13,538
New +$1.25M
INVA icon
133
Innoviva
INVA
$1.61B
$1.07M 0.06%
+42,853
New +$1.25M
AMPE
134
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.06M 0.06%
6
+5
+500% +$11.8K
MNKD icon
135
CALL
MannKind Corp
MNKD
$1.21B
$1.02M 0.06%
507
-5,611
-92% -$160K
ABUS icon
136
CALL
Arbutus Biopharma
ABUS
$871M
$967K 0.05%
+450
New +$8.09K
MDGN.WS
137
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$940K 0.05%
+817,050
New +$2.68M
PLUR icon
138
Pluri
PLUR
$18.1M
$938K 0.05%
+3,167
New +$1.02M
EXAS
139
PUT
DELISTED
Exact Sciences
EXAS
$928K 0.05%
655
-740
-53% -$9.99K
ALXA
140
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$904K 0.05%
2,040
– –
THMO
141
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$900K 0.05%
+59
New +$1.03M
OREX
142
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$896K 0.05%
138
+126
+1,050% +$8.52K
BMY icon
143
PUT
Bristol-Myers Squibb
BMY
$130B
$894K 0.05%
172
-60
-26% -$3.19K
PRTA icon
144
CALL
Prothena Corp
PRTA
$448M
$862K 0.05%
+225
New +$7.25K
XOMA
145
DELISTED
Xoma
XOMA
$858K 0.05%
8,236
-12,434
-60% -$1.81M
AVEO
146
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$857K 0.05%
57,342
-91,670
-62% -$1.65M
SRPT icon
147
CALL
Sarepta Therapeutics
SRPT
$1.63B
$843K 0.05%
351
-1,756
-83% -$44.8K
ATHE
148
CALL
Alterity Therapeutics
ATHE
$82.7M
$838K 0.05%
50
+42
+525% +$23.2K
ALIM
149
PUT
DELISTED
Alimera Sciences
ALIM
$820K 0.05%
+69
New +$6.7K
ACAD icon
150
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$810K 0.05%
333
-236
-41% -$5.97K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.